Tarlatamab added to durvalumab maintenance lengthened survival in extensive-stage small-cell lung cancer

The edition in brief

Today's oncology edition closes on DeLLphi-305, an open-label phase 3 trial of 563 patients with extensive-stage small-cell lung cancer free of progression after chemoimmunotherapy. Adding tarlatamab to durvalumab maintenance gave median overall survival of 21.1 months against 12.7 months (hazard ratio 0.42, 95% CI 0.32 to 0.54) at interim analysis, with cytokine release syndrome, mostly grade 1–2, in nearly half. VOLGA randomised 695 cisplatin-ineligible patients with muscle-invasive bladder cancer: perioperative durvalumab with three cycles of neoadjuvant enfortumab vedotin raised 24-month event-free survival to 63.5% from 45.1% with cystectomy alone, and improved overall survival (hazard ratio 0.58). Krascendo 1 found divarasib extended progression-free survival to 9.8 months from 5.7 with sotorasib or adagrasib, and overall survival to 17.7 from 12.0 months. A 100-patient trial with weekly cisplatin and radiotherapy in head and neck cancer found intravenous magnesium lowered urinary markers of kidney injury. The pearl covers kidney and electrolyte checks on weekly cisplatin.